LAM4 Antibody

What are the different types of LAM4 antibodies available for research?

LAM4 antibodies primarily refer to two distinct research tools: (1) antibodies against Laminin alpha 4 (LAMA4), a crucial extracellular matrix protein that mediates cell attachment and tissue organization during embryonic development, and (2) LaM4 nanobodies, which are single-domain antibodies that specifically bind to mCherry red fluorescent protein. Both types serve different research purposes but share the "LAM4" designation in literature .

What is the molecular basis of Laminin alpha 4 and why are antibodies against it important?

Laminin alpha 4 is a subunit of heterotrimeric glycoproteins that form major components of the basement membrane. It is a component of Laminin 411, Laminin 421, and Laminin 423. The mature Laminin alpha 4 protein contains a Laminin N-terminal domain, four Laminin EGF-like domains, a coiled-coil domain, and five C-terminal tandem Laminin G-like domains with binding sites for integrin, heparin, and dystroglycan . Antibodies against LAMA4 are important for investigating basement membrane composition, vascular development, and pathological conditions involving extracellular matrix remodeling .

How do LaM4 nanobodies differ from conventional antibodies in structure and application?

LaM4 nanobodies are significantly smaller than conventional antibodies, consisting of a single variable domain. Unlike conventional antibodies against LAMA4, LaM4 nanobodies specifically target mCherry red fluorescent protein, binding to the bottom of its β-barrel structure. This unique binding characteristic allows for targeted manipulation of mCherry-tagged proteins without significantly altering the chromophore environment, making them valuable tools for fluorescence quantification assays and live-cell imaging applications .

What are the validated applications for LAMA4 antibodies in tissue analysis?

LAMA4 antibodies have been validated for several applications including:

• Immunohistochemistry on paraffin-embedded tissues (IHC-P), particularly effective in human smooth muscle and skeletal muscle tissues

• Western blotting for protein detection in human samples, with predicted band size of 202 kDa

• Chromogenic IHC staining of frozen tissue sections

Optimal results in mouse stomach tissue have been achieved using 25 μg/mL concentration overnight at 4°C, with specific staining localized to endothelial cells in gastric pits .

How should researchers optimize storage conditions for LAM4 antibodies to maintain long-term activity?

For optimal preservation of LAM4 antibody activity:

Researchers should avoid repeated freeze-thaw cycles by dividing solutions into aliquots of no less than 20 μl for freezing at -20°C or -80°C .

What methodological approaches allow simultaneous use of LaM2 and LaM4 nanobodies with mCherry?

Crystal structure analyses at 1.4 and 1.9 Å resolution have revealed that LaM2 and LaM4 nanobodies bind to distinct, non-overlapping epitopes on mCherry. LaM2 binds to the side of the mCherry β-barrel while LaM4 binds to the bottom of the β-barrel. This structural arrangement allows both nanobodies to bind simultaneously to mCherry, enabling the recruitment of multiple operational elements to RFP-tagged proteins. The simultaneous binding capability has been verified through complementary methods including isothermal titration calorimetry, fluorescence-based size exclusion chromatography, and dynamic light scattering assays .

How can researchers validate the specificity of LAMA4 antibodies across different species?

Researchers should implement a multi-stage validation approach:

• Sequence homology analysis: Compare the amino acid sequences of the target epitope across species. For example, within the immunogenic region, mouse Laminin alpha 4 shows 91% and 97% amino acid sequence identity with human and rat Laminin alpha 4, respectively .

• Cross-reactivity testing: Perform Western blot or IHC analyses on tissues from different species under identical conditions.

• Blocking peptide validation: Use recombinant proteins or synthetic peptides corresponding to the immunogen to confirm epitope specificity.

• Knockout/knockdown controls: When available, include samples from knockout models or after siRNA-mediated knockdown.

• RNA-seq correlation: Compare antibody staining patterns with RNA expression data from the same tissues to confirm biological relevance, as demonstrated with LAMA4 antibodies in smooth muscle and skeletal muscle tissues .

What considerations should guide epitope selection when developing new antibodies against Laminin alpha 4?

Selecting optimal epitopes for Laminin alpha 4 antibody development requires:

• Structural accessibility: Target regions that are surface-exposed in the native protein structure, avoiding regions involved in heterotrimerization with beta and gamma chains.

• Domain specificity: Consider whether targeting specific domains (N-terminal, EGF-like, coiled-coil, or G-like domains) aligns with research objectives. For instance, antibodies targeting G-like domains may interfere with integrin, heparin, or dystroglycan binding .

• Sequence uniqueness: Select regions that distinguish Laminin alpha 4 from other laminin alpha chains to prevent cross-reactivity.

• Conservation across species: If cross-species reactivity is desired, target highly conserved regions. The region between Gln826-Ala1816 shows high conservation between mouse, rat, and human .

• Post-translational modification status: Consider whether potential glycosylation sites might mask epitopes or phosphorylation might alter antibody recognition, as observed with other laminin antibodies .

What methodological approaches can detect conformational changes in mCherry upon LaM4 nanobody binding?

To investigate potential conformational changes in mCherry upon LaM4 binding:

• Spectroscopic analyses: Monitor excitation and emission spectra before and after LaM4 binding to detect subtle shifts in fluorescence properties.

• Förster resonance energy transfer (FRET): Design FRET pairs to measure distance changes between different regions of mCherry upon LaM4 binding.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): Identify regions with altered solvent accessibility upon LaM4 binding, indicating conformational changes.

• Circular dichroism (CD) spectroscopy: Assess changes in secondary structure elements upon complex formation.

• Thermal shift assays: Measure changes in protein thermal stability upon LaM4 binding, indicating altered structural properties.

Current research shows that LaM4 nanobody binding does not significantly alter the chromophore environment of mCherry, unlike several GFP nanobodies that significantly affect fluorescence .

What strategies can address non-specific binding when using LAMA4 antibodies in immunostaining?

To minimize non-specific binding in LAMA4 immunostaining:

• Optimize blocking: Extend blocking time (1-2 hours) using 5-10% normal serum from the species in which the secondary antibody was raised.

• Adjust antibody concentration: Titrate LAMA4 antibodies (starting with recommended 1/50 dilution for IHC-P) to determine the minimum effective concentration .

• Modify incubation conditions: For rat anti-mouse LAMA4 antibodies, 25 μg/mL overnight at 4°C has shown specific staining in endothelial cells in gastric pits .

• Include controls: Always include isotype controls and tissues known to be negative for LAMA4 expression.

• Secondary antibody selection: Use highly cross-adsorbed secondary antibodies to reduce cross-species reactivity.

• Antigen retrieval optimization: Test different antigen retrieval methods (heat-induced vs. enzymatic) to improve specific epitope exposure while minimizing non-specific binding.

How can researchers troubleshoot inconsistent results when using LaM4 nanobodies in live-cell imaging applications?

When encountering inconsistent results with LaM4 nanobodies in live-cell imaging:

• Expression level optimization: Adjust mCherry expression levels, as excessively high or low levels may affect binding kinetics and result interpretation.

• Buffer composition: Ensure appropriate buffer conditions that maintain nanobody stability without affecting cellular viability (pH 7.2-7.4, physiological salt concentration).

• Nanobody:mCherry ratio: Titrate nanobody concentrations to determine optimal binding without saturation or excess unbound nanobody.

• Photobleaching assessment: Control for differential photobleaching rates between free and nanobody-bound mCherry.

• Temperature control: Maintain consistent temperature during imaging as binding kinetics are temperature-dependent.

• Fusion protein design: If using LaM4 as part of a fusion construct, ensure the fusion doesn't sterically hinder binding to mCherry .

What quality control measures should be implemented when purifying custom-made antibodies against LAMA4?

Essential quality control measures include:

• Binding affinity determination: Use surface plasmon resonance or biolayer interferometry to quantify antibody-antigen kinetics and affinity.

• Specificity validation: Perform Western blot analysis against recombinant LAMA4 and tissue lysates, comparing predicted (202 kDa) and observed molecular weights .

• Cross-reactivity assessment: Test reactivity against other laminin family members, particularly other alpha chains.

• Epitope mapping: Confirm the recognized epitope matches the intended target region using peptide arrays or hydrogen-deuterium exchange mass spectrometry.

• Batch-to-batch consistency: Implement robust protocols to ensure consistent performance between production batches.

• Functional validation: Verify antibody functionality in multiple applications (Western blot, IHC, IP) with appropriate positive and negative controls .

How should researchers interpret conflicting staining patterns between different LAMA4 antibodies?

When confronted with discrepant staining patterns:

• Epitope differences: Compare epitope locations of different antibodies. Antibodies targeting different domains may yield different staining patterns due to epitope accessibility in tissue contexts.

• Isoform specificity: Determine if antibodies recognize different LAMA4 isoforms or post-translationally modified variants.

• Fixation sensitivity: Assess whether differences result from variable epitope sensitivity to fixation methods. Test both paraformaldehyde-fixed and frozen sections.

• Species cross-reactivity: Verify if differences correlate with species-specific variations in the recognized epitope.

• RNA-seq correlation: Compare staining patterns with RNA expression data to determine which antibody better reflects the expected biological distribution .

• Secondary validation: Use orthogonal methods (in situ hybridization, genetic reporters) to resolve conflicting results.

What analytical approaches can quantify subtle changes in tissue distribution of LAMA4 during disease progression?

For quantitative analysis of LAMA4 distribution changes:

• Digital image analysis: Apply machine learning algorithms to segment and quantify LAMA4-positive areas in tissue sections.

• Co-localization analysis: Quantify overlap between LAMA4 and other basement membrane components or cell-type markers using Pearson's or Mander's coefficients.

• 3D reconstruction: For thick tissue sections, use confocal microscopy with z-stacking to create 3D models of LAMA4 distribution.

• Spatial transcriptomics: Correlate LAMA4 protein distribution with spatial gene expression patterns.

• Longitudinal sampling: Establish temporal progression by analyzing samples at multiple disease stages.

• Multiplexed immunofluorescence: Simultaneously detect multiple markers to contextualize LAMA4 changes within the tissue microenvironment .

How can researchers accurately distinguish between specific binding and artifactual signals when using LaM4 nanobodies in proximity-based assays?

To differentiate specific binding from artifacts in proximity assays:

• Mutational controls: Use mCherry variants with mutations at the LaM4 binding interface, which have been shown to significantly decrease binding affinity .

• Competition assays: Pre-incubate with unlabeled LaM4 to compete with labeled versions and confirm signal specificity.

• Orthogonal proximity assays: Validate findings using multiple proximity detection technologies (FRET, BiFC, BRET, PLA).

• Concentration gradients: Establish dose-response relationships to identify saturation points and non-specific binding thresholds.

• Statistical analysis: Apply appropriate statistical methods to differentiate signal from background, establishing clear significance thresholds.

• Temporal controls: Monitor binding kinetics, as specific interactions typically show characteristic association and dissociation rates that differ from non-specific binding.